Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | LTC4S | Q16873 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042709 | 0.84 | PARP14 (0.38) | CRHR1 | |
| SCHEMBL14602952 | 0.84 | GRM2 (0.33) | GRM2ARCCR4 | |
| SCHEMBL5047938 | 0.76 | RXFP1 (0.38) | CRHR1 | |
| SCHEMBL5050241 | 0.75 | TACR1 (0.39) | GRM2CRHR1CNR2LTC4SSLC6A2 | |
| SCHEMBL14602953 | 0.72 | TACR1 (0.35) | CRHR1CNR2LTC4SCCR4NPY1R | |
| SCHEMBL5043535 | 0.72 | ALDH1A1 (0.44) | CYP1A2 | |
| SCHEMBL4496282 | 0.71 | ALDH1A1 (0.46) | CRHR1CYP1A2 | |
| SCHEMBL5623905 | 0.71 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL5623938 | 0.69 | ALDH1A1 (0.46) | CYP1A2 | |
| SCHEMBL5132600 | 0.69 | CRHR1 (0.32) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| EP-1981342-B1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDYS LAB LTD DR (IN) | 2016-11-30 | — | — | EP | disclosed |
| EP-1981342-B1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDYS LAB LTD DR (IN) | 2016-11-30 | — | — | EP | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-8604055-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-12-10 | — | — | US | disclosed |
| EP-1981342-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007075194-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | GRM2 4203/4885AR 4419/4885CRHR1 4802/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | GRM2 4203/4885AR 4419/4885CRHR1 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.